Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study

Abstract Background Nafamostat mesylate is an anticoagulant used for critically ill patients during continuous kidney replacement therapy (CKRT), characterised by its short half-life. However, its optimal dosage remains unclear. This study aimed to explore the optimal dosage of nafamostat mesylate d...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Shinya Kameda, Akinori Maeda, Shun Maeda, Yutaro Inoue, Kazunari Takahashi, Akira Kageyama, Kent Doi, Tomoko Fujii
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-02-01
סדרה:	BMC Nephrology
נושאים:	Acute kidney injury Continuous kidney replacement therapy Nafamostat mesylate Filter life Anticoagulant Dose
גישה מקוונת:	https://doi.org/10.1186/s12882-024-03506-0
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!